Ung thư vú hai bên ở một bệnh nhân sống sót sau bệnh bạch cầu lymphoblast: báo cáo trường hợp

Maniar TN, Braunstein I, Keefe S, et al. Childhood ALL and second neoplasms. Cancer Biol Ther. 2007;10:1525–31. Borgmann A, Zinn C, Hartmann R, et al. Secondary malignant neoplasms after intensive treatment of relapsed Acute Lymphoblastic Leukaemia in childhood. Eur J Cancer. 2008;44:257–68. doi:10.1016/j.ejca.2007.09.019. Mody R, Li S, Dover DC, Sallan S, et al. Twenty-five–year follow-up among survivors of childhood acute lymphoblastic leukemia: a report from the childhood cancer survivor study. Blood. 2008;111:5515–23. doi:10.1182/blood-2007-10-117150. Olsen JH, Garwicz S, Hertz H, et al. Second malignant neoplasms after cancer in childhood or adolescence. Nordic Society of Paediatric Haematology and Oncology Association of the Nordic Cancer Registries. BMJ. 1993;307:1030–6. doi:10.1136/bmj.307.6911.1030. Kline N. Second malignant neoplasms. In Hockenberry-Eaton MJ, editor. Essentials of pediatric oncology. 1998. p. 264–5. Neglia JP, Maedows AT, Robison LL, et al. Second neoplasms after acute lymphoblastic leukemia in childhood. N Engl J Med. 1991;325:1330–6. Hudson MM, Tyc VL, Srivastava DK, et al. Multi-component behavioral intervention to promote health protective behaviors in childhood cancer survivors: the protect study. Med Pediatr Oncol. 2002;39:2–11. doi:10.1002/mpo.10071. Chronowski GM, Wilder RB, Levy LB, et al. Second malignancy after chemotherapy and radiotherapy for Hodgkin disease. Am J Clin Oncol. 2004;27:73–80. doi:10.1097/01.coc.0000045853.73233.42. Doung C, Hemminki K. Second primary neoplasmas among 53 159 haematolymphoproliferative malignancy patients in Sweden, 1958–1996: a case search for common mechanisms. Br J Cancer. 2001;85:997–1005. doi:10.1054/bjoc.2001.1998. Cardous-Ubbink MC, Heinen RC, Bakker PJ, et al. Risk of second malignancies in long-term survivors of childhood cancer. Eur J Cancer. 2007;43:351–62. doi:10.1016/j.ejca.2006.10.004. Ganz PA. Late effects of cancer and its treatment. Semin Oncol Nurs. 2001;17:241–8. doi:10.1053/sonu.2001.27914. Ozer E, Canda T, Kuyucuodlu F. P53 Mutations in bilateral breast carcinoma. Correlation with Ki-67 expression and the mean nuclear volume. Cancer Lett. 1998;122:101–6. doi:10.1016/S0304-3835(97)00374-1. Stenmark–Askmalm M, Gentile M, Wingren S, et al. Protein accumulation and gene mutation of p53 in bilateral breast cancer. Acta Oncologica. 2001;40:56–62. Tsavaris N, Kosmas C, Zorzos H, et al. Breast cancer after curative chemotherapy in non-Hodgkin’s lymphoma: examination of the role of drug resistance and retrospective comparison to the outcome of de novo breast cancer. Oncol Rep. 2004;11:899–903. Moore DH, Long CA, Vaidya AB, et al. Mammary tumor viruses. Adv Cancer Res. 1979;29:347–415. doi:10.1016/S0065-230X(08)60850-7. Dudley J, Arfsten A, Hsu C-HL, Kosak C, Risser R. Molecular cloning and characterization of mouse mammary tumor proviruses from T-cell lymphoma. J Virol. 1986;57:385–8. Etkind PR, Stewart AFR, Dorai T, Purcell DJ, Wiernik PH. Clonal isolation of different strains of mouse mammary tumor virus-like DNA sequences from both the breast tumors and non-Hodgkin’s lymphomas of individual patients diagnosed with both malignancies. Clin Cancer Res. 2004;10:5656–64. Wiernik PH, Etkind PR. Is mouse mammary tumor virus an etiologic agent of human breast cancer and lymphoma? South Med Assoc. 2006;99:108–10. doi:10.1097/01.smj.0000198260.49203.0f. Bhatia S, Sather HN, Pabustan OB, et al. Low incidence of second neoplasms among children diagnosed with acute lymphoblastic leukemia after 1983. Blood. 2002;99:4257–64. doi:10.1182/blood.V99.12.4257. Chaudery MA, Millis RR, Hoskins EO, et al. Bilateral primary breast cancer: a prospective study of disease incidence. Br J Surg. 1984;71:711–4. doi:10.1002/bjs.1800710924. Finney GG Jr, Finney GG, Montague CC, et al. Bilateral breast cancer, clinical and pathological review. Ann Surg. 1972;175:5. doi:10.1097/00000658-197205000-00003.